Robert Wild
Chief Scientific Officer
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Robert Wild is the Chief Scientific Officer at Dracen Pharmaceuticals, Inc., based in the United States. His research primarily focuses on the evaluation of screening markers for KEAP1/NFE2L2 mutations and their implications in tumor dynamics. Additionally, he has contributed to advancing the understanding of Sirpiglenastat (DRP-104) and its role in antitumor efficacy through modulation of glutamine metabolism and immune system stimulation.
Articles (4)
Purpose: Purine metabolism is a promising therapeutic target in cancer; however, how cancer cells respond to purine shortage, particularly their adaptation and vulnerabilities, remains unclear. Experimental Design: Using the recently developed purine shortage–inducing prodrug DRP-104 and genetic approaches, we investigated the responses in prostate, lung, and glioma cancer models. Results: We demonstrate that when de novo purine biosynthesis is compromised, cancer cells employ microtubules to assemble purinosomes, multiprotein complexes of de novo purine biosynthesis enzymes that enhance purine biosynthesis efficiency. Although this process enables tumor cells to adapt to purine shortage stress, it also renders them more susceptible to the microtubule-stabilizing chemotherapeutic drug docetaxel. Furthermore, we show that although cancer cells primarily rely on de novo purine biosynthesis, they also exploit methylthioadenosine phosphorylase (MTAP)–mediated purine salvage as a crucial alternative source of purine supply, especially under purine shortage stress. In support of this finding, combining DRP-104 with an MTAP inhibitor significantly enhances tumor suppression in prostate cancer models in vivo . Finally, despite the resilience of the purine supply machinery, purine shortage–stressed tumor cells exhibit increased DNA damage and activation of the cGAS–STING pathway, which may contribute to impaired immunoevasion and provide a molecular basis of the previously observed DRP-104–induced antitumor immunity. Conclusions: Together, these findings reveal purinosome assembly and purine salvage as key mechanisms of cancer cell adaptation and resilience to purine shortage while identifying microtubules, MTAP, and immunoevasion deficits as therapeutic vulnerabilities.
Year:
2025
Purpose: Purine metabolism is a promising therapeutic target in cancer; however, how cancer cells respond to purine shortage, particularly their adaptation and vulnerabilities, remains unclear. Experimental Design: Using the recently developed purine shortage–inducing prodrug DRP-104 and genetic approaches, we investigated the responses in prostate, lung, and glioma cancer models. Results: We demonstrate that when de novo purine biosynthesis is compromised, cancer cells employ microtubules to assemble purinosomes, multiprotein complexes of de novo purine biosynthesis enzymes that enhance purine biosynthesis efficiency. Although this process enables tumor cells to adapt to purine shortage stress, it also renders them more susceptible to the microtubule-stabilizing chemotherapeutic drug docetaxel. Furthermore, we show that although cancer cells primarily rely on de novo purine biosynthesis, they also exploit methylthioadenosine phosphorylase (MTAP)–mediated purine salvage as a crucial alternative source of purine supply, especially under purine shortage stress. In support of this finding, combining DRP-104 with an MTAP inhibitor significantly enhances tumor suppression in prostate cancer models in vivo. Finally, despite the resilience of the purine supply machinery, purine shortage–stressed tumor cells exhibit increased DNA damage and activation of the cGAS–STING pathway, which may contribute to impaired immunoevasion and provide a molecular basis of the previously observed DRP-104–induced antitumor immunity. Conclusions: Together, these findings reveal purinosome assembly and purine salvage as key mechanisms of cancer cell adaptation and resilience to purine shortage while identifying microtubules, MTAP, and immunoevasion deficits as therapeutic vulnerabilities.
Year:
2025
Our recently published K1N2-score robustly predicts KEAP1/NFE2L2 -mutations and pathway activation status, while its accessibility might be limited. We tested if the RNA expression data of six pathway-related genes and NQO1-IHC might be a reliable alternative using 348 KEAP1/NFE2L2 mutation-enriched NSCLC. While TXNRD1 RNA testing was the best-performing single-gene test, the combination of single-gene screening and validation with the K1N2-score achieved the highest performance when predicting mutation status or pathway activation.
Year:
2024
Year:
2022
Collaborators (4)
Jiaoti Huang
Professor and Chairman
Duke Medicine
Johannes Brägelmann
Professor
University Hospital Bonn
Daniel J. George
Professor
Duke University
Xia Gao
Baylor College of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.